ATEA PHARMACEUTICALS INC (AVIR)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for AVIR
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| AVIR | Independent Director | 61 | ["extensive biopharmaceutical leadership experience","CEO of DOV Pharmaceuticals","deep financial and auditing experience","CFO and Treasurer of Intercept Pharmaceuticals, Inc.","roles in Corporate Finance and Audit at Deloitte & Touche, Pepsico, Inc., SBC Warburg Dillon Read Inc., Lehman Brothers Inc."] | ["Audit","NCG","Nominating and Corporate Governance","Nominating and Corporate Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| HALO | ["Medicine and Science", "Pharma Business Leadership and Operations", "Complementary Business/Industry Segment Experience", "International Business"] | [] | 2026 |
Biography sourced from the proxy statement filing.
Barbara Duncan Independent Director Age: 61 Director Since: 2020 Class: III Committee Memberships Audit (Chair) Nominating and Corporate Governance Education Louisiana State University, BBA University of Pennsylvania, The Wharton School, MBA Qualifications and Expertise Provided to Our Board Ms. Duncan s extensive biopharmaceutical leadership experience, including her role as CEO of DOV Pharmaceuticals where she guided its acquisition, combined with deep financial and auditing experience, provides the Board with valuable expertise. Ms. Duncan s executive leadership roles at similarly scaled companies and governance insights from board roles at other public biopharmaceutical companies strengthens the Board s oversight across strategy, finance, capital allocation and governance practices. Professional Experience CFO and Treasurer of Intercept Pharmaceuticals, Inc. , a biopharmaceutical company which focused on developing treatments for liver diseases. Raised $1.5 billion through private and public financings including company s IPO and follow-ons. Collaborated in development and execution of strategic and operational plans (2009-2016) CEO (2007-2009) and CFO (2001-2007) of DOV Pharmaceuticals, Inc. , a biopharmaceutical company which focused on therapeutics primarily for treatment of central nervous system conditions. Developed and led the sale of company to Euthymics Biosciences. Executed on all phases of company s IPO, private placements and convertible debt financing raising $175 million. Roles in Corporate Finance and Audit between 1986-2000, including: o Deloitte & Touche (Senior Accountant, 1986-1989) o Pepsico, Inc. (International Auditor, 1989-1992) o SBC Warburg Dillon Read Inc. (Director, Corporate Finance, 1994-1998) o Lehman Brothers Inc. (VP, Corporate Finance, 1998-2001) Other Public Company Directorships (past five years): OVID Therapeutics Inc. (Ticker: OVID), 2017-present Halozyme, Inc. (Ticker: HALO), 2023-present Fusion Pharmaceuticals, Inc. (Ticker: FUSN), 2020-2024 Jounce Therapeutics, Inc. (Ticker: JNCE), 2016-2023 Adaptimmune, plc (Ticker: ADAP), 2016-2023 ObsEva plc (OTC, Ticker: OBSEF), 2016-2021 Core Skills Life Sciences / Healthcare Industry Business Development / Strategic Partnerships Finance & Audit M&A / Strategic Investments Senior Executive Role Corporate Governance